Using largest U.S. Database, study in low-risk patients reveals 5-year survival rate of 93%
Oct 17, 2023
Experts provide insight on the management of patients with ascending aortic aneurysm.
Date
Duration
1 hr. 35 min.

For the first time, The Society of Thoracic Surgeons joined the Korean Society for Thoracic and Cardiovascular Surgery (KSTCVS) in their presentation of the Heart Valve Disease Forum (HVDF), an annual conference that delivers the latest developments on the basis, cause, diagnosis, treatment, and future of valve disease.

Image
Heart Valve Disease Forum in Seoul

The forum, held September 15-16, 2023, in Dragon City, Yongsan, Seoul, was led by the President of the HVDF, Dr. Kyung Hwan Kim, and organized by co-program directors Dr. Joon Bum Kim of Asan Medical Center of Ulsan College of Medicine and Dr. S. Chris Malaisrie of Northwestern University, who commented “STS was thrilled to partner with the KSTCVS on this international event, highlighting transpacific expertise on valves.”

Dr. Kim remarked, “By co-hosting the forum with STS, we brought together the world’s top scholars in related fields for discussion and achieved the best conference experience.”

More than 300 surgeons, residents, and other medical students attending the conference heard from luminary surgeons and professors on today’s hottest topics impacting the specialty, including TAVI, innovative SAVR, and endocarditis, and trained on surgical techniques in wet labs. “The dynamic, case-based discussions and interactive wet labs with skilled faculty inspired the next generation of cardiac surgeons," said Dr. Malaisrie.

Dr. Thomas MacGillivray, president of STS, delivered several talks, including one on “Crisis Management in the Operating Room and Surgeon Leadership.”

At this year’s conference, particular emphasis was placed on connecting young surgeons responsible for the future of heart valve surgery with proven STS surgeon leaders through a mentor-mentee program. It was an exclusive opportunity for early career attendees to gain invaluable guidance on navigating their career paths and overcoming challenges from leaders.

“The heart valve symposium was a wonderful success and a historical event that stands out among the meeting’s 30-year history,” said Dr. Kim. “Our Korean colleagues agreed that collaborating with STS was the best thing in terms of excellence of lectures, one-to-one teaching in the wet lab, an exciting mentorship program, and beautiful times spent outside of the conference room.”

Oct 10, 2023
2 min read
The annual meeting of the Korean Society for Thoracic and Cardiovascular Surgery, presented jointly with STS
Event dates
Sep 15–16, 2023
Location
Seoul Dragon City, Seoul, Korea

On June 3, 2023, in Miami Beach, Florida, cardiothoracic surgeons from around the world convened for the second annual STS Coronary Conference. Distinguished speakers and luminary surgeons painted a modern, ever-changing landscape of coronary surgery with new technologies, such as medical robotics, increasingly integrated into the specialty daily. Attendees experienced game-changing ideas, back-to-the-basics techniques, and ground-breaking science in diagnostic and therapeutic approaches to heart disease.

“The meeting brought together international leaders in the treatment of coronary artery disease and focused on the fundamentals and advanced therapies for coronary artery disease, including medical management, arterial conduits, and minimally invasive surgical revascularization,” said Joseph F. Sabik III, MD, surgeon-in-chief and vice president for surgical operations at University Hospitals Cleveland Medical Center, and a course director of the conference. “The conversations were engaging and the atmosphere was electric.”

Sessions covered a wide range of topics, including heart team patient selection and approaches; conduit selection and harvest; non-invasive and invasive preoperative workups; and postoperative medical therapy.

Here’s a look at a few key presentations:

Two Decades of Coronary Artery Bypass Grafting in Females: Has Anything Changed?

Elizabeth Norton, MD, Emory University School of Medicine, and a team of surgeons representing the division of cardiothoracic surgery and the division of cardiology at the institution, examined trends in females undergoing isolated coronary artery bypass grafting during the past two decades. What they found is that female CABG mortality at their institution was higher than the male cohort and the overall national average and did not improve over time.​ Females undergoing isolated CABG were increasingly diverse, experienced more preoperative comorbidities, were more likely to undergo urgent CABG, and had greater IMA utilization.

External Stenting for Saphenous Vein Grafts in Coronary Surgery

Saphenous vein grafts have high failure rates with 3% to 12% occluding before hospital discharge, 8% to 25% failing at 1 year, and only 50% to 60% remaining patent after a decade.​ As a research fellow with the department of cardiothoracic surgery at Weill Cornell Medicine, Giovanni Jr. Soletti, MD, wanted to know - can neointima formation be prevented?​

By conducting a study-level meta-analysis of randomized clinical trials and other research methods, Dr. Soletti found that VEST reduces intimal hyperplasia and thickness of SVGs after CABG. This reduction does not translate into fewer graft occlusion events or repeat revascularization compared to non-VEST SVGs at a follow-up of 1.5 years. SVGs harvested with no-touch technique or arterial conduits, when clinically adequate, may be safely used to improve long-term patency. Further long-term data and larger studies are needed.

Intraoperative Extubation After Isolated CABG and Post-Operative Outcomes

There is a well-known association between post-op ventilator time and morbidity in CABG surgery. Les James, MD, a resident cardiothoracic surgeon at NYU Langone Health, explored the impact of routine OR extubation on postoperative outcomes. She studied risk factors and outcomes based on a patient’s age, BMI, EF% STS risk score, STS prolonged vent score, CPB, and XC and concluded that routine OR extubation after isolated CABG is safe and that expanded use of planned OR extubation may be warranted.

All three highlighted abstract presentations were conducted by cardiothoracic fellows. STS encourages residents and fellows to submit original research to an international expert faculty for future presentations.

Review all conference abstracts.

Jun 12, 2023
3 min read

The 2023 STS Coronary Conference returns for a second year of innovative, international, and groundbreaking science taking place June 3-4 at the Loews Miami Beach Hotel. Conference attendees will learn how to take their coronary surgery programs to the next level from a basic to an advanced program. Experts from around the world will share the latest techniques and outcomes.

Duration
1 min. 26 sec.

For patients with multivessel coronary artery disease, contemporary data analyses demonstrate that the optimal treatment is coronary artery bypass grafting (CABG), and that new downgraded recommendations for CABG could put patients at risk. 

During the STS 59th Annual Meeting in January, researchers presented compelling findings, comparing outcomes for patients who underwent CABG versus those who opted for percutaneous coronary intervention (PCI).   

“The findings of our study were very convincing,” said J. Hunter Mehaffey, MD, MSc, from the Department of Cardiovascular and Thoracic Surgery at West Virginia University. His team’s presentation, “Contemporary Artery Bypass Grafting versus Multivessel Percutaneous Coronary Intervention in 100,000 Matched Medicare Beneficiaries,” revealed that patients with blockages in multiple arteries who opt for CABG—rather than for PCI—are less likely to die from their condition, less likely to need additional surgery, and less likely to have a subsequent heart attack. 

“The singular message to the public is that the optimal treatment for multivessel coronary artery disease—to improve not only long-term survival but also lower your risk of complications—is coronary artery bypass surgery.”

- J. Hunter Mehaffey, MD 

The background and rationale for this research project started with the publication of the 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. “The cardiac surgery world was really shocked, because the guidelines downgraded the indications for CABG from a class 1 recommendation to a class 2B,” Dr. Mehaffey explained.  

Much of the decision to downgrade was based on the guideline committee’s goals to focus on the most recent data, to help ensure that they were capturing contemporary stent technology, Dr. Mehaffey explained. The guidelines therefore relied heavily on the multicenter ISCHEMIA trial, published by Maron et al in 2020. 

“ISCHEMIA wasn’t a study that was designed to look at CABG versus medical therapy in terms of survival,” said Joseph F. Sabik III, MD, chair of the Department of Surgery at UH Cleveland Medical Center in Ohio. “It was really a study that was done to look at initial conservative strategy versus an initial invasive strategy.”  

Dr. Mehaffey’s multidisciplinary team—including both surgeons and cardiologists—performed a statistical analysis of Medicare outcomes data in patients 65 and older from 2018 to 2020, including propensity score balancing to help ensure that the groups of patients who underwent stenting versus those who underwent bypass surgery were well matched in order to compare their outcomes. 

The analysis demonstrated a significantly lower hospital mortality for the patients who underwent CABG compared to those who underwent PCI. Additionally, the researchers found a marked reduction in both 30-day and 3-year readmissions for myocardial infarction. CABG patients were also significantly less likely to need any additional stenting or intervention on their coronary arteries during those 3 years, and—most significantly—those who underwent CABG had a nearly 60% reduction in death at 3 years compared to those who had PCI. 

“The singular message to the public is that the optimal treatment for multivessel coronary artery disease—to improve not only long-term survival but also lower your risk of complications—is coronary artery bypass surgery,” Dr. Mehaffey said.  

Meanwhile, Dr. Sabik’s team analyzed the past 2 years’ outcomes in the STS National Database™, which captures nearly every adult cardiac surgical procedure in the United States. “We wanted to examine how representative ISCHEMIA is for patients undergoing surgery, to see if the results are applicable,” Dr. Sabik said. 

They discovered that, based on the eligibility criteria for the ISCHEMIA trial, only about one-third of patients who underwent CABG would have been included in the study. A third would have been excluded because they had left main disease, and the other third would have met other exclusion criteria. 

“ISCHEMIA wasn’t a study that was designed to look at CABG versus medical therapy in terms of survival. It was really a study that was done to look at initial conservative strategy versus an initial invasive strategy.”  

- Joseph F. Sabik III, MD

Compared with that of the STS population, it turned out that patients who met ISCHEMIA criteria tended to have less severe disease. They didn’t have the same extent of coronary artery blockage or comorbid conditions. They tended to be younger, and they were less likely to have hypertension, diabetes, a previous stroke, peripheral vascular disease, or renal dysfunction, Dr. Sabik said. ISCHEMIA participants also were less likely to have had a myocardial infarction and more likely to have better left ventricular function. 

“Though the authors of ISCHEMIA did their best to represent patients undergoing revascularization, the study wasn’t truly representative of patients with triple-vessel disease having surgery today,” concluded Dr. Sabik. “That’s why we don’t think it should have been used to downgrade coronary surgery recommendations. People are making decisions based on these guidelines, and it may not be in the best interest of patients.” 

“This is not about surgery. It’s not about PCI, it’s not about medical therapy. It’s about making sure that patients get the right treatment, so they can have the best long-term outcomes.” 

- Joseph F. Sabik III, MD

During the 2023 C. Walton Lillehei Lecture, Peter K. Smith, MD, outlined a series of narratives that can cloud a provider’s decision-making when choosing their approach to coronary artery disease. He illuminated the nuances of commonly cited trials such as SYNTAX and FAME, detailed the evolution of common percutaneous approaches, and explained how belief in the advantages of PCI becomes murkier when the arguments aren’t equivalent. 

"There was exhaustive discussion of the age of the ‘CABG versus medical therapy’ evidence,” Dr. Smith said. “And then we entered the spin zone of indirect comparisons of ‘CABG versus medical therapy, CABG versus Stent X, Stent X versus Stent Y, Stent Y versus medical therapy—therefore CABG versus medical therapy.’ And, of course, ‘Those were all old stents and medical therapy is markedly improved now.’ This is what occurs when a core belief system is at risk.” 

“We need to work at a local level with cardiology, with heart teams, in order to make the right decisions for patients,” urged Dr. Smith. 

“This is not about surgery,” added Dr. Sabik. “It’s not about PCI, it’s not about medical therapy. It’s about making sure that patients get the right treatment, so they can have the best long-term outcomes.” 

STS 2023 registrants can watch Dr. Mehaffey’s presentation, Dr. Smith’s Lillehei Lecture, and Dr. Sabik’s late-breaking session, “The ISCHEMIA Trial Does Not Reflect Patients Undergoing Coronary Surgery: An STS Cardiac Surgery Database Analysis,” as part of their free Annual Meeting Online access. Those who didn’t register can purchase Annual Meeting Online—with special discounts for STS Members—and Resident/Fellow Members can access it for free. Visit sts.org/AMonline.  

Apr 12, 2023
5 min read

Aortic regurgitation is an undertreated condition, often because patients are not referred in a timely fashion for intervention. During this STS webinar, attendees will hear from an expert panel on the evidence base for timing of intervention as well as evolving treatment options. Conventional surgical aortic valve repair can be considered alongside the Ross procedure and transcatheter interventions with dedicated devices. Webinar participants will be better informed on how to treat this patient population.

Sponsored by JenaValve Technology, Inc. 

Date
Duration
1 hr. 3 min.

Data analyses demonstrate that new downgraded recommendations for coronary artery bypass grafting—largely based on the ISCHEMIA trial—may result in undertreatment and complications for patients with multiple blockages

Jan 23, 2023